SCD and hematologic disorder: Given considerations such as the complexities associated with ex vivo gene therapy (e.g., requiring removal of patient cells, editing cells in a laboratory, autologous transplant of cells back to the patient, myeloablative therapy, and other procedures), cost, and potential complication risk (e.g., hematologic malignancies, exacerbated by the use of conditioning regimens), a majority (>50%) of respondents in the Delphi survey exercise felt that the minimum duration of benefit that should be targeted for ex vivo SCD gene therapy would be at least 10 years.